Form 4: Carlyle Group Adjusts Medline Stake

Carlyle Group Inc. reported significant changes in its beneficial ownership of Medline Inc. Class A and Class B common stock, including a major sale and conversions.

Summary

• Carlyle Group Inc. and its affiliated entities reported multiple transactions involving Medline Inc. securities on December 18, 2025.
• 6,815,617 Common Units of Medline Holdings, LP were exchanged for an equivalent number of Medline Inc. Class A Common Stock shares.
• Concurrently, 6,815,617 shares of Medline Inc. Class B Common Stock were cancelled as a result of the Common Unit exchange, as Class B shares have no economic value and are automatically cancelled upon conversion.
• A total of 19,136,333 shares of Medline Inc. Class A Common Stock were sold at a price of $29 per share.
• An additional 1,549,243 shares of Class A Common Stock were distributed pro-rata for no consideration by Carlyle Mozart Coinvestment Holdings, L.P. to its limited partner, subject to a lock-up agreement.
• Following these transactions, Carlyle-related entities beneficially own 144,375,681 shares of Class A Common Stock and 70,927,355 Common Units/Class B Common Stock.

Sentiment

Score: 6

Explanation: The filing reports a significant sale of Class A Common Stock at a specified price, indicating value realization, alongside conversions and distributions which are standard portfolio management activities for a large investor like Carlyle. The overall reduction in direct holdings by Carlyle entities could be viewed neutrally or slightly negatively depending on the market's interpretation of their long-term commitment.

Positives

• The sale of 19,136,333 Class A Common Stock shares at $29 each represents a significant realization of value for Carlyle Group entities.
• The exchange mechanism for Common Units into Class A Common Stock provides liquidity and flexibility for investors.

Negatives

• The overall reduction in Class A Common Stock beneficial ownership by Carlyle Group entities, from an unspecified prior amount to 144,375,681 shares, could be perceived as a decrease in their direct stake.
• The distribution of 1,549,243 Class A Common Stock shares for no consideration, while a transfer within the broader Carlyle ecosystem, represents a reduction in direct holdings for the distributing entity without an immediate cash inflow.

Future Outlook

The filing does not contain any explicit forward-looking statements or guidance regarding Medline Inc.'s future performance or Carlyle Group's investment strategy beyond the reported transactions.

Industry Context

Carlyle Group, a prominent global investment firm, is managing its portfolio investment in Medline Inc., a major healthcare company. These transactions reflect typical private equity portfolio management activities, including value realization and adjustments to ownership structures, which are common in the lifecycle of such investments.

Related Party Transactions

• The reported transactions involve various entities within the Carlyle Group structure, including exchanges, sales, and distributions of Medline Inc. securities.
• The complex ownership structure detailed in footnotes 3 and 4 outlines the relationships between Carlyle Group Inc. and the various funds and entities holding Medline securities.
• The distribution of Class A Common Stock by Carlyle Mozart Coinvestment Holdings, L.P. to its limited partner is a related-party transfer.

Stakeholder Impact

• Shareholders: The market may react to the significant sale of Class A Common Stock by a major institutional investor, potentially influencing Medline's share price. The reduction in Carlyle's beneficial ownership could be interpreted as a shift in their long-term investment strategy or confidence.
• Carlyle Group Investors: The sale represents a liquidity event and value realization for the specific Carlyle funds involved, impacting their fund performance and distributions to limited partners.

Key Dates

Recommendation

The Form 4 details a significant sale of Medline Inc. Class A Common Stock by Carlyle Group entities, alongside conversions and distributions. While the sale at $29 per share indicates value realization, the overall reduction in beneficial ownership by a major investor like Carlyle could be interpreted in various ways. Without additional context on Medline's performance or Carlyle's broader investment strategy, a 'hold' recommendation is prudent, suggesting investors maintain their current positions while monitoring future developments and the market's reaction to this large transaction.

Keywords

Carlyle Group, Medline Inc., MDLN, SEC Form 4, Beneficial Ownership, Stock Sale, Equity Conversion, Private Equity, Healthcare Investment